metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology IGFBP2: a possible molecular link between liver, heart, and bloodstream during m...
Información de la revista
Vol. 29. Núm. S2.
Abstracts Asociación Mexicana del Hígado (AMH) 2023
(febrero 2024)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 29. Núm. S2.
Abstracts Asociación Mexicana del Hígado (AMH) 2023
(febrero 2024)
Acceso a texto completo
IGFBP2: a possible molecular link between liver, heart, and bloodstream during metabolic dysfunction-associated steatotic liver disease
Visitas
199
Miriam G. Bautista-Ubaldo1, Gabriela Gutiérrez-Reyes1, Ignacio González-Sánchez2, Armando Pérez-Torres3, Carolina Guzmán1
1 Laboratorio de Hígado, Páncreas y Motilidad, Unidad de Medicina Experimental, Facultad de Medicina, UNAM-Hospital General de México “Dr. Eduardo Liceaga”
2 Facultad de Química, Departamento de Biología, UNAM
3 Departamento de Biología celular y tisular, Facultad de Medicina, UNAM, Mexico City, Mexico
Este artículo ha recibido
Información del artículo
Resumen
Texto completo
Descargar PDF
Estadísticas
Suplemento especial
Este artículo forma parte de:
Vol. 29. Núm S2

Abstracts Asociación Mexicana del Hígado (AMH) 2023

Más datos
Introduction and Objectives

Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent worldwide, the concomitant presence of fibrosis is considered the most important risk factor of cardiovascular death. IGFBP2 is expressed mainly in the liver and at very low levels in heart. This peptide is associated with metabolic affection including obesity and type 2 diabetes. IGFBP2 role in MASLD is not clear. We aimed to assess the expression of IGFBP2 protein in the liver and associate it with its blood levels and cardiac expression in a rodent model of MASLD.

Materials and Patients

Male C57BL/6 mice weighing 23±2g were included and fed a high-fat diet with water added with sugar (HF-SF) or control diet up to 30 weeks. Liver damage was assessed by biopsy. IGFBP2 was assayed by ELISA in serum, liver, and heart. Data is shown as Mean±SD, analyzed by ANOVA, p<0.05.

Results

HF-SF mice exhibited increased bodyweight, visceral adiposity, and fasting glycemia compared to controls. HF-SF group developed steatosis with or without fibrosis. Mice showing fibrosis were assessed as F1C, portal fibrosis. IGFBP2 was significantly lower in steatosis regardless of the presence of fibrosis, both in serum and liver. Cardiac expression of IGFBP2 was diminished in steatosis with fibrosis compared with controls. Significant, moderate, positive correlations were observed between serum IGFBP2 and its hepatic expression, as well as IGFBP2 cardiac expression. IGFBP2 in serum negatively correlated with visceral adiposity and bodyweight.

Conclusions

IGFBP2 expression in liver and heart depends on the stage of MASLD and is associated with visceral adiposity. IGFBP2 in the bloodstream is produced mainly by the liver, and with lower contribution from heart. Serum IGFBP2 can be considered as a marker of its hepatic and cardiac expressions which are closely related with the stage of MASLD. IGFBP2 might be considered a molecular link between liver and heart during MASLD.

Texto completo

Ethical statement

All procedures were approved by CICUAL-FM-UNAM (002-CIC-2022).

Declaration of interests

None

Funding

This work was partially funded by Conacyt (221137).

Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.aohep.2024.101460
No mostrar más